The results showed that p300/CBP inhibitors, similar to FLT3 inhibitors, exhibited lower IC50 values in two FLT3-ITD AML cell lines (MV-4-11 and MOLM-13) and a FLT3-activated cell line (EOL-1) than in the FLT3-WT (RS4;11) and FLT3 null cell lines (HEL and SET-2) (Fig. 1d, e; Supplementary Fig. S1c). This evidence concerns the gene CREBBP and acute myeloid leukemia.